Biography
Dr. Bui is a Clinical Associate Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.
His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to students and trainees. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer.
His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to students and trainees. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer.
View Full Biography
Professional Summary
Education & Certifications
- Residency: Stanford University Internal Medicine Residency (2014) CA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2017)
- Fellowship: UCSD Hematology and Oncology Training (2017) CA
-
- Board Certification: American Board of Internal Medicine, Hematology (2017)
- Medical Education: University of Texas Southwestern Medical School Registrar (2011) TX
- Board Certification: American Board of Internal Medicine, Internal Medicine (2014)
- B.S., Stanford University, Computer Science (2007)
Memberships
- Member, American Society of Clinical Oncology (ASCO) (2014 - Present)
- Associate Member, Stanford Cancer Institute (2018 - Present)
- Member, Connective Tissue Oncology Society (CTOS) (2017 - Present)
-
Publications
-
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Husain, H., Nykin, D., Nam Bui, N., Quan, D., Gomez, G., Woodward, B., … Kurzrock, R. (2017). Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. MOLECULAR CANCER THERAPEUTICS, 16(5), 948–55. -
Dorsal aesthetic lines in rhinoplasty: a quantitative outcome-based assessment of the component dorsal reduction technique.
Mojallal, A., Ouyang, D., Saint-Cyr, M., Bui, N., Brown, S. A., & Rohrich, R. J. (2011). Dorsal aesthetic lines in rhinoplasty: a quantitative outcome-based assessment of the component dorsal reduction technique. Plastic and Reconstructive Surgery, 128(1), 280–88. -
Reactivation of hepatitis B virus after withdrawal of erlotinib
Bui, N., & Wong-Sefidan, I. (2015). Reactivation of hepatitis B virus after withdrawal of erlotinib. CURRENT ONCOLOGY, 22(6), 430–32. -
-
Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer
Bui, N., Woodward, B., Johnson, A., & Husain, H. (2016). Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 17(5). -
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Husain, H., Scur, M., Murtuza, A., Bui, N., Woodward, B., & Kurzrock, R. (2017). Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. MOLECULAR CANCER THERAPEUTICS, 16(2), 265–72. -
Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.
Bui, N., Henry, S., Wood, D., Wakelee, H. A., & Neal, J. W. (2017). Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC. JCO Clinical Cancer Informatics, 2017. -
Molecular insights into desmoid tumors.
Bui, N., & Kummar, S. (2017). Molecular insights into desmoid tumors. Oncotarget, 8(53), 90608–9. -
Evolution of early phase clinical trials in oncology.
Bui, N. Q., & Kummar, S. (2017). Evolution of early phase clinical trials in oncology. Journal of Molecular Medicine (Berlin, Germany). -
Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation.
Bui, N., Huang, J. K., Bojorquez-Gomez, A., Licon, K., Sanchez, K. S., Tang, S. N., … Ideker, T. (2018). Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation. Molecular Cancer Therapeutics. -
A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Bui, N., Kamat, N., Ravi, V., Chawla, S., Lohman, M., & Ganjoo, K. N. (2018). A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma. Rare Tumors, 10, 2036361318771771. -
Reviewing the role of healthy volunteer studies in drug development.
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., … Kummar, S. (2018). Reviewing the role of healthy volunteer studies in drug development. Journal of Translational Medicine, 16(1), 336. -
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Shatsky, R., Parker, B. A., Bui, N. Q., Heisten, T., Schwab, R. B., Boles, S. G., & Kurzrock, R. (2019). Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. MOLECULAR CANCER THERAPEUTICS, 18(5), 1001–11. -
Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers
Ando, M., Saito, Y., Xu, G., Bui, N. Q., Medetgul-Ernar, K., Pu, M., … Califano, J. A. (2019). Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers. NATURE COMMUNICATIONS, 10. -
Contemporary management of metastatic soft tissue sarcoma.
Bui, N. Q., Wang, D. S., & Hiniker, S. M. (2019). Contemporary management of metastatic soft tissue sarcoma. Current Problems in Cancer. -
Editorial.
Bui, N. (2019). Editorial. Current Problems in Cancer, 43(4), 249. -
A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., & Ganjoo, K. N. (2019). A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. Clinical Sarcoma Research, 9, 12. -
Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B. A., Keedy, V. L., & Davis, E. J. (2019). Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS). JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Van Tine, B. A., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B.-W., Chawla, S. P., … Hirbe, A. C. (2019). A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Dose escalation of tinostamustine in patients with advanced solid tumors
Mita, A., Loeffler, M., Bui, N., Mehrling, T., Rimmel, B. J., Natale, R. B., & Kummar, S. (2019). Dose escalation of tinostamustine in patients with advanced solid tumors. CANCER RESEARCH, 79(13). -
Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria.
Chen, J. W., Kunder, C. A., Bui, N., Zehnder, J. L., Costa, H. A., & Stehr, H. (2020). Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria. Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing, 25, 31–42. -
Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid.
Tabata, M. M., Novoa, R. A., Bui, N. Q., & Zaba, L. C. (2020). Successful treatment of HIV-negative Kaposi sarcoma with ipilimumab and nivolumab and concurrent management of baseline psoriasis and bullous pemphigoid. JAAD Case Reports, 6(5), 447–49. -
Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H.-C. C., & Ganjoo, K. (2020). Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. Immunotherapy. -
Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H.-C., & Ganjoo, K. (2020). Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review. IMMUNOTHERAPY, 12(18), 1303–12. -
SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS
Bhadri, V., Bui, N., Guminski, A., Oneto, J. M., Murthy, R., Sankhala, K., … Yee, N. (2020). SQ3370-001 IS A MULTI-CENTER OPEN-LABEL PHASE I DOSE-ESCALATION STUDY TO TEST A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO TREAT ADVANCED SOLID TUMORS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M. A., … Schwartz, G. K. (2020). NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma. JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma.
Brewster, R., Purington, N., Henry, S., Wood, D., Ganjoo, K., & Bui, N. (2021). Evaluation of Absolute Lymphocyte Count at Diagnosis and Mortality Among Patients With Localized Bone or Soft Tissue Sarcoma. JAMA Network Open, 4(3), e210845. -
Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.
Zhou, M., Bui, N., Lohman, M., van de Rjin, M., Hwang, G., & Ganjoo, K. (2021). Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression. Case Reports in Oncology, 14(1), 459–65. -
Evolving role of entrectinib in treatment of NTRK-positive tumors.
Chawla, N., Bui, N. Q., & Seetharam, M. (2021). Evolving role of entrectinib in treatment of NTRK-positive tumors. Future Oncology (London, England). -
Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.
Tolwani, A., Matusiak, M., Bui, N., Forgo, E., Varma, S., Baratto, L., … Przybyl, J. (2021). Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. NPJ Genomic Medicine, 6(1), 30. -
Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.
Yurkiewicz, I. R., Zhou, M., Ganjoo, K. N., Charville, G. W., Bolleddu, S., Lohman, M., & Bui, N. (2021). Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course. American Journal of Clinical Oncology. -
Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib.
Testa, S., Million, L., Longacre, T., & Bui, N. (2021). Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib. Case Reports in Oncology, 14(2), 812–819. -
Phase 1 trial of SQ3370 in solid tumors.
Guminski, A., Wang, D., Bui, N., Bhadri, V., De Silva, M., Steffner, R., … Subbiah, V. (2021). Phase 1 trial of SQ3370 in solid tumors. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma.
Doshi, A., Zhou, M., Bui, N., Wang, D. S., Ganjoo, K., & Hwang, G. L. (2021). Safety and Feasibility of Cryoablation during Immunotherapy in Patients with Metastatic Soft Tissue Sarcoma. Journal of Vascular and Interventional Radiology : JVIR. -
Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria
Chen, J. W., Kunder, C. A., Bui, N., Zehnder, J. L., Costa, H. A., & Stehr, H. (2020). Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria. PACIFIC SYMPOSIUM ON BIOCOMPUTING 2020. WORLD SCIENTIFIC PUBL CO PTE LTD. -
Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review.
Zhou, M., Javadi, C., Charville, G. W., Bui, N. Q., Harris, E. J., Poultsides, G. A., … Ganjoo, K. N. (2021). Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review. Surgical Oncology, 39, 101670. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Van Tine, B. A., Hirbe, A. C., Luo, J., Oppelt, P. J., Weiss, M. C., Eulo, V. A., … Ganjoo, K. N. (2021). Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Ingham, M., Allred, J. B., Gano, K., George, S., Attia, S., Burgess, M. A., … Schwartz, G. K. (2021). NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.
Testa, S., Hu, B. D., Saadeh, N. L., Pribnow, A., Spunt, S. L., Charville, G. W., … Ganjoo, K. N. (2021). A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma. Current Oncology (Toronto, Ont.), 28(6), 5304–5317. -
A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma
Lanman, T., Hayden, M., Bui, N., & Nagpal, S. (2021). A Case of Isolated Leptomeningeal Progression in a Patient with NTRK Fusion plus Uterine Sarcoma. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
Przybyl, J., Spans, L., Ganjoo, K., Bui, N., Mohler, D., Norton, J., … van de Rijn, M. (2022). Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma. PloS One, 17(1), e0262272. -
Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.
Testa, S., Bui, N. Q., Wang, D. S., Louie, J. D., Sze, D. Y., & Ganjoo, K. N. (2022). Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas. Cancers, 14(2). -
Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report.
Lanman, T., Hayden Gephart, M., Bui, N., Toland, A., & Nagpal, S. (2021). Isolated Leptomeningeal Progression in a Patient with NTRK Fusion+ Uterine Sarcoma: A Case Report. Case Reports in Oncology, 14(3), 1841–1846. -
WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma.
Ponce, R. K., Thomas, N. J., Bui, N. Q., Kondo, T., & Okimoto, R. A. (2022). WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma. JCI Insight, 7(6). -
PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM
Bhadri, V., Subbiah, V., Strauss, J., Chawla, S., Bui, N., Kwatra, V., … Guminski, A. (2021). PHARMACOKINETIC AND IMMUNOLOGIC DATA FROM A PHASE I STUDY OF THE CLICK CHEMISTRY-BASED THERAPY SQ3370 IN ADVANCED SOLID TUMORS AND SOFT-TISSUE SARCOMA PROVIDES PROOF-OF-CONCEPT FOR THE CAPAC PLATFORM. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP. -
Current management and recent progress in desmoid tumors.
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ghanouni, P., & Ganjoo, K. N. (2022). Current management and recent progress in desmoid tumors. Cancer Treatment and Research Communications, 31, 100562. -
The interaction of SWI/SNF with the ribosome regulates translation and confers sensitivity to translation pathway inhibitors in cancers with complex perturbations.
Ulicna, L., Kimmey, S. C., Weber, C. M., Allard, G. M., Wang, A., Bui, N. Q., … Van Rechem, C. (2022). The interaction of SWI/SNF with the ribosome regulates translation and confers sensitivity to translation pathway inhibitors in cancers with complex perturbations. Cancer Research. -
Cutaneous Angiosarcoma of the Head and Neck-A Retrospective Analysis of 47 Patients.
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., & Ganjoo, K. (2022). Cutaneous Angiosarcoma of the Head and Neck-A Retrospective Analysis of 47 Patients. Cancers, 14(15). -
Interactions in CSF1-driven Tenosynovial Giant Cell Tumors.
van IJzendoorn, D. G., Matusiak, M., Charville, G. W., Spierenburg, G., Varma, S., Colburg, D. R., … van de Rijn, M. (2022). Interactions in CSF1-driven Tenosynovial Giant Cell Tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting.
Testa, S., Bui, N. Q., Charville, G. W., Avedian, R. S., Steffner, R., Ghanouni, P., … Ganjoo, K. N. (2022). Management of Patients with Newly Diagnosed Desmoid Tumors in a First-Line Setting. Cancers, 14(16). -
Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
Bose, S., Ingham, M., Chen, L., Kochupurakkal, B., Marino-Enriquez, A., Allred, J. B., … Schwartz, G. K. (2022). Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Interim phase 1 results for SQ3370 in advanced solid tumors.
Chawla, S. P., Batty, K., Aleckovic, M., Bhadri, V., Bui, N., Guminski, A. D., … Kwatra, V. (2022). Interim phase 1 results for SQ3370 in advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis.
Liu, L., Dehner, C., Grandhi, N., Lyu, Y., Borcherding, D. C., Chrisinger, J. S., … Hirbe, A. C. (2022). The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis. Genes, 13(11). -
Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy.
Baniel, C., Yoo, C. H., Jiang, A., von Eyben, R., Mohler, D. G., Ganjoo, K., … Hiniker, S. M. (2022). Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy. Practical Radiation Oncology. -
Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma.
Zhou, M., Bui, N., Rathore, R., Sudhaman, S., George, G. V., Malashevich, A. K., … Ganjoo, K. N. (2022). Feasibility of Longitudinal ctDNA Assessment in Patients with Uterine and Extra-Uterine Leiomyosarcoma. Cancers, 15(1). -
Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors.
Gounder, M., Ratan, R., Alcindor, T., Schoffski, P., van der Graaf, W. T., Wilky, B. A., … Kasper, B. (2023). Nirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors. The New England Journal of Medicine, 388(10), 898–912. -
The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies.
Kim, T., & Bui, N. Q. (2023). The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies. Cancers, 15(6). -
SQ3370 in advanced solid tumors: Interim phase 1 results.
Chawla, S. P., Batty, K., Bhadri, V., Bui, N., Guminski, A. D., Oneto, J. M. M., … Kwatra, V. (2022). SQ3370 in advanced solid tumors: Interim phase 1 results. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis.
Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., … Moding, E. J. (2023). Monitoring sarcoma response to immune checkpoint inhibition and local cryotherapy with circulating tumor DNA analysis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma.
Bui, N., Dietz, H., Farag, S., Hirbe, A. C., Wagner, M. J., Van Tine, B. A., … Davis, E. J. (2023). A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma. Cancers, 15(9). -
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.
Zhou, M. Y., Bui, N. Q., Charville, G. W., Ganjoo, K. N., & Pan, M. (2023). Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy. International Journal of Molecular Sciences, 24(11). -
Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis.
Testa, S., Bui, N. Q., & Ganjoo, K. N. (2023). Systemic Treatments and Molecular Biomarkers for Perivascular Epithelioid Cell Tumors: A Single-institution Retrospective Analysis. Cancer Research Communications, 3(7), 1212–1223. -
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
Ingham, M., Allred, J. B., Chen, L., Das, B., Kochupurakkal, B., Gano, K., … Schwartz, G. K. (2023). Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2300402. -
Management Strategies and Outcomes in Primary Liver Angiosarcoma.
Ramakrishnan, N., Mokhtari, R., Charville, G. W., Bui, N., & Ganjoo, K. (2023). Management Strategies and Outcomes in Primary Liver Angiosarcoma. American Journal of Clinical Oncology. -
Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma
Van Tine, B. A., Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., … Wilky, B. A. (2023). Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study
Van der Graaf, W. T. A., Gounder, M. M., Ratan, R., Ivanescu, C., Marcus, J., Bell, T., … Kasper, B. (2023). Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Sex-Dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N. Q., Bien, J., … Ganjoo, K. N. (2023). Sex-Dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy.
Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G., Sears, T. J., Somani, A., … Moding, E. J. (2024). Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy. Nature Cancer. -
LBA11504 Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.
Eulo, V., Toeniskoetter, J., Ruff, T., Luo, J., Kemp, L., Moreno Tellez, C., … Wilky, B. A. (2023). LBA11504 Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma. JOURNAL OF CLINICAL ONCOLOGY, 41(17_SUPPL), LBA11504. -
Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy
Lee, A. Q., Hao, C., Pan, M., Ganjoo, K. N., & Bui, N. (2024). Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Prognostic factors for patients with sarcoma with brain metastases
Zhang, E., Farag, S., Dietz, H., Wang, D. Y., Hirbe, A. C., Ganjoo, K. N., … Bui, N. (2024). Prognostic factors for patients with sarcoma with brain metastases. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study
Alshibany, A., Zhou, M., Warren, E. A., Ganjoo, K. N., Demicco, E., Feeney, J., … Razak, A. R. A. (2024). Molecular residual disease (MRD) detection using bespoke circulating tumor DNA (ctDNA) assays in localized soft tissue sarcoma (STS): A multicenter study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study
Vincenzi, B., Bui, N., Dileo, P., Federman, N., Riedel, R. F., Van Tine, B. A., … Kasper, B. (2024). Efficacy of nirogacestat in participants with poor prognostic factors for desmoid tumors: Analyses from the randomized phase 3 DeFi study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis
Bui, N., Kwatra, V., Ryan, C. W., Gordon, E. M., Aleckovic, M., Srinivasan, S., … Chawla, S. P. (2024). Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma.
Pan, M., Zhou, M. Y., Jiang, C., Zhang, Z., Bui, N., Bien, J., … Habel, L. A. (2024). PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcoma. BJC Reports, 2(1), 9. -
Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study.
Zhang, E., Farag, S., Dietz, H., Wang, D., Hirbe, A., Ganjoo, K., … Bui, N. (2024). Brain Metastases in Sarcomas: A Multicenter Retrospective Cohort Study. Cancers, 16(22). -
Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma.
Lee, A. Q., Hao, C., Pan, M., Ganjoo, K. N., & Bui, N. Q. (2024). Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers.
Pan, M., Zhou, M., Xie, L., Bui, N., & Ganjoo, K. (2024). Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers. Journal of Hematology & Oncology, 17(1), 124.
-
Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Study of Cryoablation and Nirogacestat for Desmoid Tumor
- Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
- A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
- A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
- A Study of AL102 in Patients With Progressing Desmoid Tumors
- A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Practice Locations
Sarcoma Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Sarcoma Program in Palo Alto
900 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereSarcoma Program in South Bay San Jose, CA
San Jose, CA
Sarcoma Program in South Bay
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereMedical Oncology Program in South Bay San Jose, CA
San Jose, CA
Medical Oncology Program in South Bay
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereCancer Center in South Bay San Jose, CA
San Jose, CA
Cancer Center in South Bay
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(190 reviews)
Dr. Bui is an excellent doctor. He is always knowledgeable, encouraging and informative. I am glad he is part of my care team.
Dr. Bui is extremely efficient with his visits.
I have always had a good visit with Dr Bui
Dr. Bui has consistently shown professionalism and caring during every visit. I am lucky to be in his care.
Thorough with great explanations. Doesn't leave anything to chance.
Thorough Friendly
He’s the Best!
Dr Bui is very easy to talk to. He answers questions thoroughly and takes the time to listen to concerns. I am glad to have him on my cancer team.
We look forward to our visits
He is very kind and he followed with a phone call the same day, and we spoke !
I feel fortunate to have had a session with Dr. Bui.
Thank you
Excellent Caring doctor
Dr presented me with a timeframe for the new treatment. This seemed to be very accurate and helpful for continuing my treatment. Thank you Dr Bui
Dr. Bui is a very good listener. He's patient and made me feel like he had all the time in the world to hear my concerns. He helped me with decisions today and gave me options for treatments. I felt very relieved in his presence.
He's been good.
Every person I came in contact with either in person or on the phone was kind and professional.
Dr. Bui continues to convey confidence and positive energy. He began the session with a big smile followed by a celebratory “the MRI indicates cancer free†. He was as happy as I was. Although a very busy doctor, Dr. Bui takes time to answer questions with details and honestly. I appreciate that he avoids medical jargon and speaks clearly and with the right tone. I feel fortunate to have Dr. Bui managing my sarcoma experience.
Grateful for Dr. Bui’s care.
Dr. Bui is very clear in explaining my case andfollowup needed.
Dr. Bui is excellent. I’m privileged to have him on my care team.
He is a very nice and personable Dr.
Dr. Bui was very professional and encouraging. I feel like I'm in very good hands and he cares about me and my health.
He is a wonderful doctor!
All good!!
He's a great doctor and I like him. He's always very thorough and makes sure I understand.
Dr. Nam Bui has provided excellent care. He is very knowledgable, kind, professional, and thorough which I greatly appreciate.
Dr Bui has been very supportive, answered all our questions
Bedside manner needs improvement. Often directs comments and attention to person with patient rather than directly to the patient.
Dr. Bui has been an amazing doctor. I have always felt like Dr. Bui has always put the best interests of his patients first.
Dr. Bui is very knowledgeable, friendly and seems to care for me as a patient. He has always answered my daughter’s questions as well as mine. I am blessed to have him as my doctor. I would highly recommend him to other patients.
Bery kind and patient.
I really like Dr. Bui. He has been a great doctor to have thru out this whole process.
Dr. Bui is always upbeat and extremely helpful. I feel privileged to have him as my oncology care doctor, and would recommend him to anyone having a sarcoma such as mine.
He's easy to talk to and has a good demeanor and very informative and positive oh hi very knowledgeable
Ver personable and good communications.
Dr Bui is a very good Doctor and we have worked together for over two years.. my comment for consideration is regarding communication approaches in unfortunate situations when a radiology report may contain challenging information for the patient. I have regular scans and typically results are released to me within 24 hours or so after the scan. Thus, when a patient does not receive the results prior to an appointment, one naturally becomes concerned and anxiety can be elevated. I just wonder if perhaps there can be a way to accelerate engagement with patients in these instances to reduce any anxiety of somewhat extended time periods. I am not faulting doctors or staff in the slightest here, as such planning is not always possible, but I do wonder if some protocol might be helpful in these instances.
Dr. Bui answered all my questions
very good listener
answered questions very well
kind
He seems like a nice person.
He is very attentive and is professional. He understood what I needed for treatment and made great recommendations!
Dr. Bui continues to be very knowledgeable, encouraging, positive and flexible.
Dr. Bui is doing a great job with my care and I appreciate all his efforts and ideas, as I travel this road of recovery. I appreciate his input when concerns arise and his ability to listen while navigating future care, thoughts, ideas, and concerns.
Very clear with info
Nam Buiis is very easy to communicate with. Very friendly .
He is extremely thorough with everything that needs to be followed up on. Within minutes, those concerns are book and I don’t have to wait several months to be seen again. I appreciate that more than anything.
I am confident that he has the expertise and education to provide me with excellent health care.
good doctor and communicator
He seemed very thorough. I fully understood what he said.
Very professional and thorough regarding my test results. The doctor answered all my questions/concerns.
It Was a fine visit.
Dr Bui does a great job of listening and understanding my symptoms and concerns. He does an excellent job in navigating my care. I appreciate the opportunity of expressing my personal thoughts and ideas, while moving forward with my care.
Great Doctor, very diligent.
Dr. Nam Bui is an excellent, extremely knowledgeable and caring physician. I highly recommend him as a physician.
For about three years Dr. Bui has successfully managed my sarcoma, and I am delighted to be repetitive by saying he remains exceptional. I value his medical expertise and his very special human qualities. He can be counted on to have reviewed very carefully my scans and other medical data and to answer my questions thoroughly, clearly, and honestly. He was very encouraging of my physical therapy treatment, sharing an example from his own experience. I was surprised that he asked about my birthday after obviously seeing the date on my chart. He listened attentively as I relived the joyful day.
Working with his nurse Heidi and other staff is also a very helpful and pleasant experience. Dr. Bui continues to exude positive energy in spite of his very busy schedule. No cliche ... I always look forward to talking with Dr. Bui and feel so fortunate to have him as my sarcoma oncologist.
I have enjoyed working with Dr. Bui got over two years now. His professionalism and empathy are a great comfort to me and my family.
Dr. Bui was compassionate and listened to my concerns. He answered my concerns and is proactive in making sure I get the best treatment.
Dr Bui is patient in listening and understanding the realities of my illness and offers great ideas and plans to move forward with treatment(s). I value his insight, ideas, thoughts, and perspectives on the path to healing. I try to follow the path of best practices and we seem to find our way to being on the same page, lock n step.
Very thorough and explains his analysis of the situation very well. Good listener.
Really appreciate Dr. Bui. He’s kind and answers all my questions thoroughly.
He's always been respectful has a wonderful personality. Has always answered all my questions. From the first day I talked to him he was always very positive. I'm glad I have been receiving care from him recommended by my urologist in Carson City Nevada.
Dr Bui is very caring to his patients and talking about details at patient treatment. Very grateful Dr Bui. Thank you
Thank you..
Dr. Bui is concerned about my health and quality of life. He offers ideas and options. He probes.
Excellent care. Thanks Dr Bui!
Dr Nam Bui listen his patients very carefully and give me satisfaction answers all my questions about my treatment. Thank you
I appreciate him and his expertise.. it was a pleasure having him as my doctor.
Dr.Bui is very friendly and I was extremely satisfied with his recommendation for my health issues.
He is very personable! And he asks questions
He made a good impression.
He is great
I am very pleased with this doctor and would give him the highest rating
Absolutely love his bedside manner
Dr. Bui was very professional and had answered all my questions and concerns regarding my situation. Also, he was thorough on follow up recommendations and scheduling for follow ups regarding my health.
I enjoyed meeting him.
Very professional and personable!
Excellent care by Dr. Nam Bui. Would highly recommend him to other patients needing assistance.
Dr Bui very pleasant, answered all questions.
Dr. Bui clearly has medical expertise but also human qualities He exudes positive energy and calmness during the discussion. The latter seems important for those of us on this challenging experience with cancer. I always look forward to meetings with him. He listens attentively, answers questions honestly and explains clearly--no use of medical jargon or cliches. He makes sure that I know the next steps or processes. I value very much his advice and remain grateful that my former oncologist referred my case to him.
We were able to come to a plan on my care which i am happy with.
Excellent visit! Very helpful and informative.
Extremely kind and patient. Answered all my questions so this way I can make an informed decision going forward.
Outstanding Doctor!!!
Dr. Bui is always ready and available for questions. His one follow up was to request that Stanford radiologists do second review of most recent CT scan
Dr Bui has been doing an excellent job and is very professional and understanding with medical information. He is open to various discussions about health and the healing process.
Extremely caring and very interested in my medical condition. He will call me back after he presents my case to the tumor board.
Great Dr.
He is doing a great job. Thank you.
I am happy to have Dr. Bui in my corner.
I like the fact he gives solutions to figure it out things right away
He was very knowledgeable, but very kind as well
Dr. Nam Bui addressed all of my medical concerns.
I was very impressed with him.
I really enjoy having Dr. Bui as my physician. He is thorough in his discussions with me and comes to my appointments well prepared.
I saw Dr. Bui for a 2nd opinion the day I called, thanks to a cancellation. Despite short notice, he was up to date on my case history. He was thoughtful and kind, gave us more time than scheduled. I am organizing transfer of my care to him.
Dr Bui made it easy for me to talk to him and ask questions.
Dr. Bui was extremely professional and understanding during my video call with him. I am dealing with cancer issues which can make myself and my family very anxious. His reassuring manner calmed a lot of nerves in my family and myself.
excellent Doctor - answers all my question clearly
Dr. Bui is an amazing doctor.
Dr. Bui Was very helpful in sharing his screen of images that helped us understand the situation. He explains the options and possible outcomes in a manner we can understand.
We are very confident that Dr. Bui is providing the best care possible.
Superb
I am looking forward to our next visit and a plan for my illness. Dr. Bui seems to have it all under control.
Excellent visit with Nam Bui. Greatly appreciate the care given by Stanford Health and Dr. Nam Bui.
Dr. Bui was friendly, informative and made me feel comfortable even though it was a video call. I look forward to meeting him in person.
Dr Bui is great! Always explains to me exactly what is going on, options and very up best, nice and professional
Dr. Bui is great. I really appreciate everything he has done for me. I honestly feel he cares about my well-being. I highly recommend Stanford to family and friends.
Dr Bui was very understanding with my concerns and stayed cognizant after the news took time to sink in. We even revisited questions and concerns and he was reassuring I had understood the direction for treatment.
Dr. Bui is an outstanding doctor. He explained everything that I wanted to know.
Doctor Bui is extraordinary. The "very good" category on this survey is inadequate. Others would also most definitely value havig Doctor Bui as their sarcoma specialist. He has a quiet manner and is soft spoken, but the information he provides and his response to questions reveal a remarkable, caring and supportive clinician.
My husband and I greatly appreciate Dr Bui and his care for me through the past few years. We would recommend him to anyone we know without hesitation. He always responds to my questions quickly and provides information in a kind and caring way.
He is an excellent doctor, and is relatable.
Felt that he cares
Wonderful doctor.
The physician I consulted was exceptional. The general staff were courteous, professional, and polite.
Happy with Dr Bui over the years..
He’s knowledgeable and helpful!
Excellent doctor.
Excellent doctor and communicator
This was a good experience for the visit.
Very happy with Dr. Bio’s care.
Excellent doctor. Sick, so not in clinic.
Excellent service
He is very detailed and goes through every piece of my health treatment plan with care. He has all of the answers that help me understand my health and make decisions. I feel like my care is being watched very closely.
Excellent doctor, very soothing to talk to
Very caring individual
Dr Bui was knowledgeable, friendly and accommodating. I am glad I had an appointment with him and I may work with him on a clinical trial in the future (I am currently not eligible for the trial).
Excellence by all technicians and nurses
He has always giving me the most professional care that I could ask for. He has a good bedside manner as well. I always feel well informed when I speak with him.
Excellent doctor.
I had a great visit and greatly appreciate Dr. Nam Bui.
I think he is knowledgeable and can be a great asset in partnering with a local oncologist for my continued care.
Dr. Bui is very helpful and answers my questions very clearly.
Great job.
He is very knowledgeable and frank. I appreciated that.
Dr. Bui is always upbeat, and he's great about keeping me on the chemo so I don't relapse.
Excellent
I thank Dr. Nam Bui and appreciate him for all the wonderful health care that he provide to and for me. May God continue to bless Dr. Nam Bui in his medical profession!
He was very kind, patient, and supportive
Dr. Bui always makes sure that all of my questions are answered before the end of the visit.
Dr. Nam Bui provided an excellent video health visit.
I have trust in what he has to say.
Listened carefully to my questions
Excellent doctor. Attentive, always answers all my questions
I think he is an excellent doctor, very informative and makes you feel at ease
He is excellent
I enjoy our conversations .
Dr. Bui is always ready to listen and I appreciate that!
Dr. Bui was thorough, competent, and easy to talk with.
I am very happy to be in his care.
Excellent doctor who really CARES about his patients -- and follow up!
Great Visit!
He is an excellent doctor. Always answers our questions in detail. I can’t say enough about him
Dr. Bui takes his time and answers my questions in a way I understand. Dr. Bui is very patient and understanding.
I always feel that my questions get answered and answered in a way that I can understand. He often tells me that he will put in an order, and usually within a day or two I am contacted by them to make an appointment.
He and his staff are very flexible with scheduling whenever possible which is a good thing for me since I am self-employed and do not have a regular schedule daily or weekly.
He is an excellent doctor. Very kind and patient with me. I feel I am in excellent care.
He knows what he is doing. I trust him.
I feel very comfortable with Dr. Bui
Excellent
He was very reassuring and I appreciate him answering all my questions in an understandable way.
Dr. Bui conveys information clearly and patiently, answers questions and reveals knowledge relating to my illness in a humane, thoughtful way which I appreciate. He also shows concern and joy as results of scans have shown my condition improved.
Great person to deal with.
One of the best
Excellent communicator; answers patient questions; provides hope for on-going recovery.
He is a very excellent Doctor. Dr. Is very helpful. Me and my wife are extremely thankful for him to help us with my cancer. Would definitely recommend to anyone else that I know if they ever get sick.
God Bless Dr. Bui.
He seems to care a great deal about my healt and well being
very nice
Excellent doctor.
Dr. Bui seems like a nice and knowledgeable person.
Doctor Bui was great and answered all questions
Grateful grateful for him and his plan for treatment
Grateful to have Dr. Bui as my oncologist
Very good doctor he explained everything Very good
Excellent doctor. Patient and informative
He is great
Great Dr
Very informative, did a great job walking me through the process and explaining each step.
I am very grateful to have him as my doctor.
Dr. Bui is able to keep track of my particular situation and is available for consulting by email.
He is okay not to many questions.
Very caring
Excellent
The staff is very good with all the patients in general.
It must be that every patient should recommend the best of cares that I needed -
You guys are great! Thank you.
Dr. Bui & his team are awesome. Even though I am getting treated in Visalia they assist every step of the way.
Always very professional giving the answer to my questions.
I would recommend all very good experience.
Dr. is always pleasant and cheerful.
All very good.
Good very appreciated helpful and care they provides for me and my families.
A very good experience, I was very well treated. Thank God and all the staff.
Excellent service and I would come again.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records